Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Required: MET amplification

documentation of NSCLC with MET amplification determined by FMI tissue-based next generation sequencing (NGS) assay

Required: EGFR sensitizing mutation

Participants must not have other known actionable oncogenic alterations, such as (but not limited to) EGFR sensitizing mutations, EGFR T790M mutation, MET Exon-14 skipping mutant NSCLC, ALK gene fusion, ROS1 gene rearrangement, RET gene rearrangement, NTRK rearrangement, HER2 mutation, KRAS activating mutations, and BRAF V600E mutation

Required: EGFR T790M mutation

Participants must not have other known actionable oncogenic alterations, such as (but not limited to) EGFR sensitizing mutations, EGFR T790M mutation, MET Exon-14 skipping mutant NSCLC, ALK gene fusion, ROS1 gene rearrangement, RET gene rearrangement, NTRK rearrangement, HER2 mutation, KRAS activating mutations, and BRAF V600E mutation

Required: MET Exon-14 skipping mutant

Participants must not have other known actionable oncogenic alterations, such as (but not limited to) EGFR sensitizing mutations, EGFR T790M mutation, MET Exon-14 skipping mutant NSCLC, ALK gene fusion, ROS1 gene rearrangement, RET gene rearrangement, NTRK rearrangement, HER2 mutation, KRAS activating mutations, and BRAF V600E mutation

Required: ALK fusion

Participants must not have other known actionable oncogenic alterations, such as (but not limited to) EGFR sensitizing mutations, EGFR T790M mutation, MET Exon-14 skipping mutant NSCLC, ALK gene fusion, ROS1 gene rearrangement, RET gene rearrangement, NTRK rearrangement, HER2 mutation, KRAS activating mutations, and BRAF V600E mutation

Required: ROS1 rearrangement

Participants must not have other known actionable oncogenic alterations, such as (but not limited to) EGFR sensitizing mutations, EGFR T790M mutation, MET Exon-14 skipping mutant NSCLC, ALK gene fusion, ROS1 gene rearrangement, RET gene rearrangement, NTRK rearrangement, HER2 mutation, KRAS activating mutations, and BRAF V600E mutation

Required: RET rearrangement

Participants must not have other known actionable oncogenic alterations, such as (but not limited to) EGFR sensitizing mutations, EGFR T790M mutation, MET Exon-14 skipping mutant NSCLC, ALK gene fusion, ROS1 gene rearrangement, RET gene rearrangement, NTRK rearrangement, HER2 mutation, KRAS activating mutations, and BRAF V600E mutation

Required: NTRK1 rearrangement

Participants must not have other known actionable oncogenic alterations, such as (but not limited to) ... NTRK rearrangement ...

Required: NTRK2 rearrangement

Participants must not have other known actionable oncogenic alterations, such as (but not limited to) ... NTRK rearrangement ...

Required: NTRK3 rearrangement

Participants must not have other known actionable oncogenic alterations, such as (but not limited to) ... NTRK rearrangement ...

Required: HER2 (ERBB2) mutation

Participants must not have other known actionable oncogenic alterations, such as (but not limited to) ... HER2 mutation ...

Required: KRAS activating mutation

Participants must not have other known actionable oncogenic alterations, such as (but not limited to) ... KRAS activating mutations ...

Required: BRAF V600E mutation

Participants must not have other known actionable oncogenic alterations, such as (but not limited to) ... BRAF V600E mutation ...

Must have received: systemic therapy — Stage IV or recurrent NSCLC

Participants must have received at least one line of systemic treatment for Stage IV or recurrent NSCLC; must have progressed (in the opinion of the treating physician) following the most recent line of therapy

Cannot have received: MET tyrosine kinase inhibitor (tepotinib, capmatinib, crizotinib)

Participants must not have been previously treated for any cancer with MET tyrosine kinase inhibitors (TKIs) such as tepotinib, capmatinib, and crizotinib

Cannot have received: systemic therapy

Exception: within 21 days prior to sub-study registration

Participants must not have received any prior systemic therapy (systemic chemotherapy, immunotherapy or investigational drug) within 21 days prior to sub-study registration

Cannot have received: anti-PD-1 therapy

Exception: within 6 weeks of sub-study registration

Participants must not have had prior treatment with anti-PD-1 or anti-PD-L1 antibody within 6 weeks of sub-study registration

Cannot have received: radiation therapy

Exception: within 14 days prior to sub-study registration

Participants must not have received any radiation therapy within 14 days prior to sub-study registration